HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial

NCT04743765 · tracked via the Priya Life Science India tracker

Sponsor

Population Health Research Institute

Phase

Not applicable

Started

2021-11-22

Last updated

2026-08-26

Condition(s) studied

Hip FracturesMyocardial Injury

Investigational drug(s) / intervention(s)

Accelerated medical clearance and surgery

Accelerated medical clearance and surgery: Rapid medical clearance with targeted arrival to the operating room within 6 hours of eligibility criteria criteria met.

Study summary

The HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. The trial will also assess secondary outcomes at 90 days after randomization: inability to independently walk 3 metres, time to first mobilization (first standing and first full weight bear), composite and individual assessment of major complications (e.g., mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke), delirium, length of stay, pain, and quality of life.

Eligibility

Sex

ALL

Min age

45 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. age ≥45 years; 2. diagnosis of hip fracture during working hours with a low-energy mechanism requiring surgery; 3. troponin elevation ( at least one troponin measurement above the upper limit of normal occurring from the time of hip fracture to the time of randomization); and 4. informed consent. Exclusion Criteria: 1. taking a therapeutic dose of an anticoagulant for which no reversing agent is available and the anesthesiologist or surgeon believe surgery within 6 hours of eligibility criteria met would not be safe; 2. patients on a therapeutic vitamin K antagonist with a history of heparin induced thrombocytopenia (HIT); 3. patients with peri-prosthetic fracture, open fracture or bilateral fractures; 4. patients requiring an emergency surgery for another reason (e.g., subdural hematoma); 5. patients with acute myocardial infarction deemed to be clinically unstable, with a mechanical complication (i.e., acute papillary muscle rupture, ventricular septal defect), ST elevation myocardial infarction, or cardiogenic shock; 6. patients refusing consent; or 7. patients previously enrolled in HIP ATTACK-2.

Primary outcome measure(s)

All cause mortality — Within 90 days post randomization
Death due to all causes

Trial sites (77)

Facility	City	Region	Status
Chandler Regional Medical Center	Chandler	Arizona	Active Not Recruiting
The Regents of the University of California	Davis	California	Active Not Recruiting
University of California, Irvine	Irvine	California	Active Not Recruiting
Yale New Haven Hospital	New Haven	Connecticut	Active Not Recruiting
Emory University at Grady Memorial Hospital	Atlanta	Georgia	Active Not Recruiting
University of Maryland	Baltimore	Maryland	Active Not Recruiting
Sinai Hospital of Baltimore	Baltimore	Maryland	Active Not Recruiting
Tufts Medical Center	Boston	Massachusetts	Active Not Recruiting
Lahey Hospital and Medical Center	Burlington	Massachusetts	Active Not Recruiting
University of Michigan	Ann Arbor	Michigan	Active Not Recruiting
Mayo Clinic	Rochester	Minnesota	Active Not Recruiting
Bryan Medical Center	Lincoln	Nebraska	Active Not Recruiting
University Medical Center of Southern Nevada	Las Vegas	Nevada	Active Not Recruiting
Dartmouth-Hitchcock Medical Center	Lebanon	New Hampshire	Active Not Recruiting
Montefiore Medical Center	The Bronx	New York	Active Not Recruiting
Cleveland Clinic	Cleveland	Ohio	Active Not Recruiting
Oregon Health and Science University	Portland	Oregon	Active Not Recruiting
St. Luke's University Health Network	Bethlehem	Pennsylvania	Active Not Recruiting
The University of Texas Southwestern Medical Center (UTSW)	Dallas	Texas	Active Not Recruiting
The University of Texas Health Science Center at Houston	Houston	Texas	Active Not Recruiting
University of Utah	Salt Lake City	Utah	Active Not Recruiting
University of Wisconsin	Madison	Wisconsin	Active Not Recruiting
Froedtert Hospital	Milwaukee	Wisconsin	Active Not Recruiting
The John Hunter Hospital	New Lambton Heights	New South Wales	Recruiting
Cliniques Universitaires Saint Luc - University Catholic of Louvain	Woluwe-Saint-Lambert	Brussels Capital	Active Not Recruiting
University of São Paulo	São Paulo	São Paulo	Recruiting
University of Alberta Hospital	Edmonton	Alberta	Active Not Recruiting
St. Joseph's Healthcare Hamilton	Hamilton	Ontario	Recruiting
Juravinski Hospital	Hamilton	Ontario	Recruiting
Victoria Hospital	London	Ontario	Recruiting
Markham Stouffville Hospital	Markham	Ontario	Recruiting
Ottawa General Hospital	Ottawa	Ontario	Recruiting
CISSS de Laval	Laval	Quebec	Recruiting
Pontifica Universidad Catolica de Chile	Santiago	RM	Recruiting
Clinica Santa Maria	Santiago	Chile	Recruiting
South Karelia Central Hospital	Lappeenranta	Finland	Active Not Recruiting
Tampere University Hospital	Tampere	Finland	Recruiting
Queen Mary Hospital	Hong Kong	Hong Kong	Recruiting
Bangalore Baptist Hospital	Bangalore	Karnataka	Recruiting
Government TD Medical College	Alappuzha	Kerala	Active Not Recruiting

+ 37 more sites — see the full list on the official registry below.

More Population Health Research Institute trials in India

Prospective Urban Rural Epidemiology Study Recruiting

Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease Recruiting

Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04743765 on ClinicalTrials.gov ↗ ← All trials in India